Novo Nordisk has ended its partnership with Hims & Hers Health Inc., citing “deceptive marketing” and the selling of ...

Harbour BioMed has partnered with Otsuka Pharmaceutical Co., Ltd. to advance BCMAxCD3 bispecific T-cell engagers for the ...

Cellular Origins has entered into a collaboration with Johnson & Johnson to develop a scalable, end-to-end automated platform ...

Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK. The opening ceremony was ...

PharmaLogic Holdings Corp., a CDMO, has completed its previously announced acquisition of a majority stake in Agilera Pharma.

Aversa Fentanyl combines Nutriband’s Aversa abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch.

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Will support spray drying and unit operations including granulation, encapsulation, compression and coating for oral dosage ...

This will support the advancement of a novel ophthalmic therapeutic through clinical development and onto the market.

They aim to transform output and labor requirements for CGT manufacturing using automated robotics manufacturing capabilities ...

The expansion will add 9,000 square feet to its Massachusetts facility, expanding development and production capabilities.

Together, they will find partners for the development of the ‘RSH Olfactory Delivery Device,’ a dual nostril intranasal ...